Clinical Decision Tool Cuts Inappropriate BMA Therapy in Prostate Cancer
SAN DIEGO — An algorithm-based decision tool eliminated inappropriate prescribing of bone-modifying agents (BMA) in patients with advanced prostate cancer, according to a VA-based study. Prior to implementing the tool, inappropriate BMA prescribing was found in more than 50% of cases of men with metastatic sensitive-resistant prostate cancer (mCSPC) without bone metastases at the George […]